We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Aridis

News List

Aridis Reports Positive Preclinical Efficacy Data for Inhaled Treatment for COVID-19 americanpharmaceuticalreview
October 23, 2020
Aridis Pharmaceuticals announced the development of a highly neutralizing monoclonal antibody AR-711, discovered from convalescent COVID-19 patients that successfully eliminated all detectable SARS-CoV-2 virus in infected animals at ...
Aridis Receives Orphan Drug Designation from the EMA for AR-501 americanpharmaceuticalreview
July 22, 2019
ridis Pharmaceuticals announced the European Medicines Agency (EMA) has granted Orphan Drug Designation to AR-501, the Company's inhaled formulation of gallium citrate for treatment of lung infection in patients with cystic fibrosis.
AR-501 Enrolls First Subject in Trial for Treatment of CF Chronic Lung Infections americanpharmaceuticalreview
December 13, 2018
Aridis Pharmaceuticals announced the first subject has been enrolled in a Phase 1/2a clinical study evaluating the investigational candidate AR-501 for treatment of chronic bacterial lung infections in patients with cystic fibrosis (CF).....